Movement and Beyond: Symptoms and the Road Ahead
At a Glance
PRKN-related Parkinson disease often begins with leg or foot twisting, slowness, or stiffness rather than tremor and usually progresses slowly. Levodopa often works well, but mood, sleep, wearing-off, involuntary movements, and emergency symptoms still need medical attention.
Living with PRKN-related Parkinson’s disease (PRKN-PD) often means navigating a clinical course that looks quite different from the traditional understanding of Parkinson’s. While the “classic” image of the disease involves a resting tremor in an older adult, PRKN-PD frequently begins with unique motor challenges and a much slower overall pace [1][2].
Early Motor Signs: The Lower-Limb Connection
For many with PRKN-PD, the first sign of the condition isn’t a tremor, but rather a change in how they walk or move their legs.
- Lower-Limb Dystonia: This is one of the most hallmark early symptoms of PRKN-PD [3]. Dystonia refers to involuntary muscle contractions that cause repetitive or twisting movements. In this condition, it often manifests as a foot that “turns in” or toes that “curl” during a walk or run [4][5]. This can make gait (your style of walking) feel clumsy or difficult long before other symptoms appear [2].
- The “Absent” Tremor: While a resting tremor can occur, it is often absent in the earliest stages of PRKN-PD [6]. Instead, you may notice bradykinesia (slowness of movement) or rigidity (muscle stiffness), particularly in the legs [7].
- Sleep Benefit: A possible and sometimes reported feature of PRKN-PD is that motor symptoms may improve after a night of sleep or even a brief nap, a variable phenomenon known as “sleep benefit” [8]. While helpful to log in a symptom diary, do not use this to self-adjust your medication doses without clinical guidance.
A Slower Pace: Disease Progression
One of the most encouraging aspects of PRKN-PD is its generally slow motor progression compared to late-onset disease [1].
- Long-Term Mobility: People with this genetic form of the disease typically maintain their ability to walk and perform daily tasks for longer than those with typical late-onset Parkinson’s [1].
- Levodopa Response and Complications: Most people with PRKN-PD have an excellent and sustained response to levodopa (the gold-standard Parkinson’s medication) [9]. However, motor complications like dyskinesia (involuntary “wiggling” movements) and “wearing-off” will eventually occur. While studies suggest these may develop later on average than in some other early-onset groups, young-onset patients have a long lifetime of treatment exposure, meaning these complications do occur and can sometimes develop relatively early in your treatment history [1][8]. Always report any returning stiffness or writhing movements to your doctor.
Impactful Non-Motor Symptoms
While PRKN-PD is associated with a lower average risk of early dementia (meaning memory and executive function often remain sharp), it does not mean non-motor symptoms are absent [2]. In fact, certain non-motor issues are prevalent and can deeply affect quality of life [2].
- Mood Disorders: High rates of depression and anxiety are common among those with PRKN-PD, often appearing early in the diagnosis [2][8].
- Sleep Challenges: You may experience excessive daytime sleepiness or other sleep disorders that leave you feeling unrefreshed [2][8].
- Preserved Cognition: Unlike typical Parkinson’s, which can involve significant cognitive decline in later stages, PRKN-PD is generally characterized by the maintenance of memory and executive function, though “brain fog” from fatigue, depression, or medications can still occur [10].
Atypical Signs and “Red Flags” vs. Emergencies
Because PRKN-PD typically follows a predictable, slow course, certain symptoms are considered “atypical” (diagnostic red flags) and should be discussed with your neurologist [11]. These suggest your diagnosis or treatment needs a review, but are not immediate emergencies:
- Rapid Progression: Going from initial symptoms to needing a wheelchair within just a few years is highly unusual for PRKN-PD [11][12].
- Early Severe Cognitive Decline: Significant memory loss or confusion in the first few years [13].
- Poor Response to Medication: If your symptoms do not improve at all with an adequate trial of levodopa [11].
Medical Emergencies:
The following symptoms require immediate, urgent medical care:
- Sudden “sleep attacks” while driving or operating machinery.
- Repeated severe falls leading to injury, or fainting/loss of consciousness.
- Sudden, acute confusion, hallucinations, or suicidal thinking.
- Choking or severe difficulty swallowing [14].
Common questions in this guide
What are the earliest symptoms of PRKN-related Parkinson disease?
Does PRKN-related Parkinson disease usually progress quickly?
Does levodopa work well for PRKN-related Parkinson disease?
How is foot dystonia addressed in PRKN-related Parkinson disease?
Can depression, anxiety, or sleep problems occur even if memory stays preserved?
Which symptoms should prompt a review of the diagnosis or treatment plan?
Which symptoms require immediate medical care?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Movement and walking
What can be done about dystonia or changes in walking?
Tracking symptoms
Should I keep a symptom diary to bring to my appointments?
Mood and sleep
What support is available for depression, anxiety, or daytime sleepiness?
Get notified when new evidence is published on Autosomal recessive juvenile Parkinson disease 2.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Genotype-phenotype correlation in PRKN-associated Parkinson's disease.
Menon PJ, Sambin S, Criniere-Boizet B, et al.
NPJ Parkinson's disease 2024; (10(1)):72 doi:10.1038/s41531-024-00677-3.
PMID: 38553467 - 2
Quality of Life in Newly Diagnosed Patients With Parkin-Related Parkinson's Disease.
Zhou XY, Liu FT, Chen C, et al.
Frontiers in neurology 2020; (11()):580910 doi:10.3389/fneur.2020.580910.
PMID: 33391150 - 3
Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review.
Kasten M, Hartmann C, Hampf J, et al.
Movement disorders : official journal of the Movement Disorder Society 2018; (33(5)):730-741 doi:10.1002/mds.27352.
PMID: 29644727 - 4
Dopa-responsive dystonia or early-onset Parkinson disease - Genotype-phenotype correlation.
Potulska-Chromik A, Hoffman-Zacharska D, Łukawska M, Kostera-Pruszczyk A
Neurologia i neurochirurgia polska 2017; (51(1)):1-6 doi:10.1016/j.pjnns.2016.07.013.
PMID: 27667361 - 5
PARK2 Patient Presenting with Dopa-Responsive Dystonia.
Yoshii F, Aono K, Kumazawa R, Takahashi W
Case reports in neurology 2021; (13(3)):749-754 doi:10.1159/000520436.
PMID: 35082644 - 6
Animal Models of Autosomal Recessive Parkinsonism.
Bastioli G, Regoni M, Cazzaniga F, et al.
Biomedicines 2021; (9(7)) doi:10.3390/biomedicines9070812.
PMID: 34356877 - 7
A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics.
Cornejo-Olivas MR, Torres L, Mata IF, et al.
Parkinsonism & related disorders 2015; (21(5)):444-8.
PMID: 25817512 - 8
Pediatric-onset PRKN disease: New insights into an understudied population.
Gonul Oner O, Biboulet Bruneau C, Fraix V, et al.
Journal of Parkinson's disease 2024; (14(8)):1631-1641 doi:10.1177/1877718X241296153.
PMID: 39957199 - 9
Precision Dopaminergic Treatment in a Cohort of Parkinson's Disease Patients Carrying Autosomal Recessive Gene Variants: Clinical Cohort Data and a Mini Review.
Koros C, Simitsi AM, Papagiannakis N, et al.
Neurology international 2024; (16(4)):833-844 doi:10.3390/neurolint16040062.
PMID: 39195564 - 10
Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study.
Tan MMX, Malek N, Lawton MA, et al.
Brain : a journal of neurology 2019; (142(9)):2828-2844 doi:10.1093/brain/awz191.
PMID: 31324919 - 11
Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases.
Fox SH, Luca DG, Postuma RB, et al.
NPJ Parkinson's disease 2025; (11(1)):360 doi:10.1038/s41531-025-01206-6.
PMID: 41390531 - 12
Parkinson disease primer, part 1: diagnosis.
Frank C, Chiu R, Lee J
Canadian family physician Medecin de famille canadien 2023; (69(1)):20-24 doi:10.46747/cfp.690120.
PMID: 36693741 - 13
Diagnosis and Treatment of Cognitive and Neuropsychiatric Symptoms in Parkinson Disease and Dementia With Lewy Bodies.
Weintraub D, Irwin D
Continuum (Minneapolis, Minn.) 2022; (28(5)):1314-1332 doi:10.1212/CON.0000000000001151.
PMID: 36222767 - 14
Multiple system atrophy.
Poewe W, Stankovic I, Halliday G, et al.
Nature reviews. Disease primers 2022; (8(1)):56 doi:10.1038/s41572-022-00382-6.
PMID: 36008429
This page is for informational purposes only and does not constitute medical advice about PRKN-related Parkinson disease. Your neurologist should interpret symptom changes, guide levodopa adjustments, and advise you about urgent warning signs.